Compare Stocks → A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CNATNASDAQ:CTICNASDAQ:GEMPNASDAQ:MRKRNASDAQ:VCNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNATConatus Pharmaceuticals$0.50$1.00$0.23▼$1.07$16.59M1.841.28 million shs525 shsCTICCTI BioPharma$9.09$9.06$4.01▼$9.10$1.20B0.834.50 million shsN/AGEMPGemphire Therapeutics$3.44-0.6%$4.97$0.24▼$1.49$51.16M2.82127,174 shs22,787 shsMRKRMarker Therapeutics$4.10-4.9%$4.26$0.76▼$9.68$36.49M1.521,056 shs13,050 shsVCNXVaccinex$4.80-0.8%$8.11$4.43▼$100.80$5.90M0.7411,855 shs11,069 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNATConatus Pharmaceuticals0.00%0.00%+51.52%+31.58%-59.02%CTICCTI BioPharma0.00%0.00%0.00%0.00%+102.90%GEMPGemphire Therapeutics-3.68%-3.68%-26.09%+0.59%+343.92%MRKRMarker Therapeutics-2.05%-11.13%-0.23%-0.46%+302.80%VCNXVaccinex+1.68%-28.72%-40.98%-37.14%-94.74%A.I. Pioneer Issues Urgent Warning to Americans (Ad)With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.Click here to see Louis' new video for yourself.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNATConatus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACTICCTI BioPharma0.0443 of 5 stars1.00.00.00.00.61.70.6GEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNATConatus PharmaceuticalsN/AN/AN/AN/ACTICCTI BioPharma2.00Hold$9.00-0.99% DownsideGEMPGemphire TherapeuticsN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNATConatus Pharmaceuticals$21.72M0.76N/AN/A$0.53 per share0.94CTICCTI BioPharma$53M22.62N/AN/A($0.14) per share-64.93GEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AMRKRMarker Therapeutics$3.31M11.02N/AN/A$1.58 per share2.60VCNXVaccinex$570K10.36N/AN/A($2.59) per share-1.85Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNATConatus Pharmaceuticals-$11.39MN/AN/A∞N/A-52.42%-48.22%-39.32%N/ACTICCTI BioPharma-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/AGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AMRKRMarker Therapeutics-$8.24MN/A0.00∞N/A-142.62%-39.89%-25.45%5/21/2024 (Estimated)VCNXVaccinex-$20.25M-$100.86N/A∞N/AN/A-2,667.31%-571.70%5/20/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNATConatus PharmaceuticalsN/AN/AN/AN/AN/ACTICCTI BioPharmaN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNATConatus PharmaceuticalsN/A16.2816.28CTICCTI BioPharmaN/A1.271.26GEMPGemphire TherapeuticsN/A0.670.67MRKRMarker TherapeuticsN/A5.575.57VCNXVaccinexN/A0.570.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNATConatus Pharmaceuticals15.20%CTICCTI BioPharma91.45%GEMPGemphire Therapeutics17.53%MRKRMarker Therapeutics22.39%VCNXVaccinex50.11%Insider OwnershipCompanyInsider OwnershipCNATConatus Pharmaceuticals11.30%CTICCTI BioPharma7.61%GEMPGemphire Therapeutics22.70%MRKRMarker Therapeutics24.10%VCNXVaccinex51.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNATConatus Pharmaceuticals3033.17 millionN/ANot OptionableCTICCTI BioPharma127131.88 million121.84 millionOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableMRKRMarker Therapeutics678.90 million6.76 millionNot OptionableVCNXVaccinex381.23 million598,000OptionableVCNX, MRKR, CTIC, CNAT, and GEMP HeadlinesSourceHeadlineVaccinex faces Nasdaq compliance challengeinvesting.com - April 14 at 7:54 AMVCNX Stock Earnings: Vaccinex Reported Results for Q4 2023investorplace.com - April 2 at 3:02 PMVaccinex Reports 2023 Financial Results and Provides Corporate Updateglobenewswire.com - April 2 at 8:30 AMVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - March 27 at 8:30 AMVaccinex CFO Scott Royer to retire, Jill Sanchez steps ininvesting.com - March 6 at 7:15 PMVaccinex Inc VCNXmorningstar.com - March 2 at 3:46 PMVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technologyfinanznachrichten.de - February 21 at 9:42 AMVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery Platformmarkets.businessinsider.com - February 21 at 9:42 AMVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technologyfinance.yahoo.com - February 21 at 9:42 AMVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technologyglobenewswire.com - February 21 at 8:00 AMVaccinex Announces 1-For-14 Reverse Stock Splitmarkets.businessinsider.com - February 15 at 4:28 PMWhy Vaccinex (VCNX) Stock Is Trading Lowermsn.com - February 15 at 4:28 PMVaccinex, Inc. Announces Reverse Stock Splitglobenewswire.com - February 15 at 8:00 AMSteven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Incfinance.yahoo.com - February 12 at 2:49 PMVaccinex Inc Secures $3.7M in Private Placement Dealmsn.com - February 8 at 10:26 AMWhy Vaccinex (VCNX) Stock Is Popping Offmsn.com - February 7 at 2:45 PMVaccinex Announces Pricing of $3.7 Million PIPE Financingmarkets.businessinsider.com - February 7 at 9:45 AMA phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.ascopubs.org - January 30 at 7:55 PMNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rulefinance.yahoo.com - December 4 at 8:50 AMVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 13 at 9:59 AMVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meetingfinance.yahoo.com - October 31 at 11:18 AMVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseasesfinance.yahoo.com - October 26 at 9:40 AMUnderstanding the Risks of Investing in Vaccinex Inc (VCNX)knoxdaily.com - October 17 at 9:03 PMVaccinex Inc [NASDAQ: VCNX] Sees Decrease in Stock Valueknoxdaily.com - October 6 at 7:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsConatus PharmaceuticalsNASDAQ:CNATConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.CTI BioPharmaNASDAQ:CTICCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.Gemphire TherapeuticsNASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Marker TherapeuticsNASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.VaccinexNASDAQ:VCNXVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.